Tantisira Kelan G, Weiss Scott T
Brigham and Women's Hospital and Harvard Medical School, Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115, USA.
Curr Opin Mol Ther. 2005 Jun;7(3):209-17.
Responses to the three major classes of asthma therapy, beta-agonists, leukotriene antagonists and inhaled corticosteroids, demonstrate wide inter-individual variability. Moreover, both asthma and the traits measured in response to asthma therapy, including forced expiratory volume at 1 s, are highly heritable. This indicates that genetics may play a prominent role in the determination of the therapeutic response to asthma. The human genetic association trials that investigate responses to each of the three major classes of asthma therapy will be summarized, and recent findings in the literature highlighted. Altogether, the available data indicate that genetics influences the likelihood of an individual responding to a given therapy, indicating that, in the future, optimal care for individuals with asthma may include genetic testing.
对哮喘治疗的三大主要类别（β-激动剂、白三烯拮抗剂和吸入性糖皮质激素）的反应显示出个体间存在很大差异。此外，哮喘以及对哮喘治疗的反应所测量的特征，包括1秒用力呼气量，都具有高度遗传性。这表明遗传学可能在哮喘治疗反应的决定中起重要作用。本文将总结针对哮喘治疗三大主要类别中每一类反应的人类基因关联试验，并突出文献中的最新发现。总体而言，现有数据表明遗传学影响个体对特定治疗产生反应的可能性，这表明未来对哮喘患者的最佳治疗可能包括基因检测。
